You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial
|
|---|---|
| Published in |
Trials, June 2014
|
| DOI | 10.1186/1745-6215-15-226 |
| Pubmed ID | |
| Authors |
Sian Robinson, Aleksander Zincuk, Ulla Lei Larsen, Claus Ekstrøm, Palle Toft |
| Abstract |
Previous pharmacokinetic trials suggested that 40 mg subcutaneous enoxaparin once daily provided inadequate thromboprophylaxis for intensive care unit patients. Critically ill patients with acute kidney injury are at increased risk of venous thromboembolism and yet are often excluded from these trials. We hypothesized that for critically ill patients with acute kidney injury receiving continuous renal replacement therapy, a dose of 1 mg/kg enoxaparin subcutaneously once daily would improve thromboprophylaxis without increasing the risk of bleeding. In addition, we seek to utilize urine output prior to discontinuing dialysis, and low neutrophil gelatinase-associated lipocalin in dialysis-free intervals, as markers of renal recovery. |
Mendeley readers
The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 86 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 16% |
| Student > Postgraduate | 11 | 13% |
| Student > Bachelor | 11 | 13% |
| Student > Ph. D. Student | 11 | 13% |
| Other | 8 | 9% |
| Other | 15 | 17% |
| Unknown | 18 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 47% |
| Nursing and Health Professions | 7 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Engineering | 5 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 2% |
| Other | 6 | 7% |
| Unknown | 22 | 25% |